BioNTech progresses CAR-T cell therapy in solid tumors

Germany’s BioNTech (Nasdaq: BNTX) has presented positive Phase I/II on its CAR-T cell therapy candidate BNT211 in advanced solid tumors at the European Society of Medical Oncology (ESMO) Congress 2023.

BNT211 combines two innovative approaches in one regimen with first-in-class potential, these being an autologous CAR-T cell therapy targeting the oncofetal antigen Claudin-6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).

The data demonstrates that the application of CARVac increases the persistence of the adoptively transferred autologous CAR-T cells, showing encouraging signs of clinical activity.